Skip to main content
Clinical Trials/NCT04539834
NCT04539834CompletedNot Applicable

Electrolyte State in Patients With COVID-19

Zagazig University1 site in 1 country983 target enrollmentStarted: May 1, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
983
Locations
1
Primary Endpoint
electrolytes disturbances in patients with COVID-19

Study Overview

Brief Summary

Initial case reports and cohort studies have described many clinical characteristics of patients with coronavirus disease 2019 (COVID-19), an emerging infectious disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In early COVID-19 studies, some evidence has been provided that electrolyte disorders may also be present upon patients' presentation, including sodium, potassium, chloride and calcium abnormalities

the aim of the study is Identification of elements that affect COVID-19 pathology to improve survival and decrease mortality rate.

Detailed Description

SARS-CoV-2 invades human cells through binding angiotensin I converting enzyme 2 (ACE2) on the cell membrane. ACE2 is widely distributed in many types of human tissues, especially in the vital organs, such as heart, liver, kidney, and lungs. ACE2 is viewed as the principal counter-regulatory mechanism for the main axis of renin-angiotensin system (RAS) that is an essential player in the control of blood pressure and electrolyte balance. The final effect is to increase reabsorption of sodium and water, and thereafter increase blood pressure and excretion of potassium (K+). Besides, patients with COVID-19 often had gastrointestinal symptoms such as diarrhea and vomiting

Early studies proved that high percentage of COVID-19 patient were presented with electrolyte disorders, including sodium, potassium, chloride and calcium abnormalities. Such electrolyte disturbances have important implications not only for patient management but also for identifying potential pathophysiologic mechanisms underlying COVID-19 that could drive novel therapeutic opportunities

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients ≥ 18 years old who were confirmed by the real-time PCR on the respiratory tract samples as positive of SARS-CoV-2.

Exclusion Criteria

  • Patients who had other causes of electrolyte disturbances (9):
  • Chronic organ dysfunction (e.g., hepatic or renal dysfunction),
  • Terminal cancer, immunodeficiency, and
  • Patients with a history of long-term use of hormones & Diuretics were excluded.

Outcomes

Primary Outcomes

electrolytes disturbances in patients with COVID-19

Time Frame: 4 months

Serum Electrolytes (Na, K, Ca, Cl, Ph, Mg) abnormality in COVID 19 patients laboratory results in the different stages of the disease

Secondary Outcomes

  • To asses the relation of the electrolyte disturbances with the severity of COVID-19 infection.(4 months)

Investigators

Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

Essamedin Mamdouh Negm

lecturer

Zagazig University

Study Sites (1)

Loading locations...

Similar Trials